Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Classifica tra le azioni #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Prezzo delle azioni
$0.25974701
Ultima sincronizzazione: 2025-01-06
Capitalizzazione di mercato
$2.04M
Variazione (1 giorno)
0.74%
Variazione (1 anno)
0.00%
Paese
FR
Scambia Acticor Biotech SAS (ALACT)

Categoria

Storico del rendimento da dividendi per Acticor Biotech SAS (ALACT)
Il rendimento da dividendi (TTM) di Acticor Biotech SAS (simbolo azionario: ALACT) al 2022-12-31 è: 0.00%
Rendimento medio negli ultimi 5 anni: 0.00%
Storico del rendimento da dividendi per Acticor Biotech SAS (ALACT) da 2010 a 2026
Rendimento da dividendi alla fine di ogni anno (TTM)
Anno Rendimento da dividendi Cambia
2026 (TTM) 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
2014 0.00% 0.00%
2013 0.00% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
2010 0.00% 0.00%
Rendimenti da dividendi (TTM) di aziende simili o concorrenti
Azienda Rendimento da dividendi Il paese
0.00%
US
0.00%
NL
2.36%
AU
0.00%
US
0.00%
CH